Acelyrin, Inc. SLRN
We take great care to ensure that the data presented and summarized in this overview for ACELYRIN, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in SLRN
Top Purchases
Top Sells
About SLRN
Insider Transactions at SLRN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 17
2024
|
Daniel J. Becker Director |
SELL
Open market or private sale
|
Direct |
1
-0.03%
|
$6
$6.86 P/Share
|
|
May 15
2024
|
Mina Kim Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,230
-8.46%
|
$40,920
$4.47 P/Share
|
|
May 15
2024
|
Melanie Gloria Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,298
-7.33%
|
$41,192
$4.47 P/Share
|
|
May 15
2024
|
Sanam Pangali CLO & Head of People |
SELL
Payment of exercise price or tax liability
|
Direct |
921
-1.23%
|
$3,684
$4.47 P/Share
|
|
Apr 01
2024
|
Shao Lee Lin Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
9,961
-0.63%
|
$59,766
$6.63 P/Share
|
|
Feb 20
2024
|
Shao Lee Lin Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,701
-0.98%
|
$109,907
$7.6 P/Share
|
|
Jan 02
2024
|
Shao Lee Lin Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
10,691
-0.66%
|
$74,837
$7.41 P/Share
|
|
Oct 04
2023
|
Paul Peloso Chief Medical Officer |
BUY
Other acquisition or disposition
|
Indirect |
39,133
+50.0%
|
-
|
|
Oct 04
2023
|
Shao Lee Lin Chief Executive Officer |
BUY
Other acquisition or disposition
|
Indirect |
132,236
+21.35%
|
-
|
|
Oct 04
2023
|
Shao Lee Lin Chief Executive Officer |
SELL
Other acquisition or disposition
|
Indirect |
1,161,747
-100.0%
|
-
|
|
Oct 04
2023
|
Patrick Machado Director |
BUY
Other acquisition or disposition
|
Indirect |
14,675
+50.0%
|
-
|
|
Oct 04
2023
|
Gil M Labrucherie CFO and CBO |
BUY
Other acquisition or disposition
|
Indirect |
40,763
+50.0%
|
-
|
|
Aug 16
2023
|
Ronald Oyston Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
140,332
+49.82%
|
-
|
|
Aug 16
2023
|
Melanie Gloria Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
140,584
+50.0%
|
-
|
|
Aug 16
2023
|
Mina Kim Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
114,676
+48.93%
|
-
|
|
Aug 16
2023
|
Paul Peloso Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
115,511
+48.73%
|
-
|
|
Aug 16
2023
|
Shao Lee Lin Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
842,400
+34.32%
|
-
|
|
May 09
2023
|
Westlake Bio Partners Fund Ii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,250,000
+11.32%
|
$22,500,000
$18.0 P/Share
|
|
May 09
2023
|
Westlake Bio Partners Fund Ii, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
8,540,729
+50.0%
|
-
|
|
May 09
2023
|
Dawn Svoronos Director |
BUY
Open market or private purchase
|
Direct |
15,000
+50.0%
|
$270,000
$18.0 P/Share
|
Last 12 Months Summary
Buy / Acquisition
0
Shares
From
0
Insiders
Sell / Disposition
57.8K
Shares
From
5
Insiders
| Open market or private sale | 36.4K shares |
|---|---|
| Payment of exercise price or tax liability | 21.4K shares |